Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

A Safety and Tolerability Study of Azilsartan Medoxomil in Participants With Essential Hypertension

ClinicalTrials.gov ID: NCT00696384

Public ClinicalTrials.gov record NCT00696384. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 11:44 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An 8-Month Phase 3, Open-Label Study With a Blinded Reversal Phase to Evaluate the Safety and Tolerability of TAK-491 in Subjects With Essential Hypertension

Study identification

NCT ID
NCT00696384
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Takeda
Industry
Enrollment
418 participants

Conditions and interventions

Conditions

Interventions

  • Azilsartan medoxomil Drug
  • Azilsartan medoxomil, with or without chlorthalidone and other non-angiotensin II receptor blocker antihypertensive medications. Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 31, 2007
Primary completion
Mar 31, 2009
Completion
Mar 31, 2009
Last update posted
Jan 3, 2012

2007 – 2009

United States locations

U.S. sites
33
U.S. states
22
U.S. cities
33
Facility City State ZIP Site status
Not listed Huntsville Alabama
Not listed Chandler Arizona
Not listed Mesa Arizona
Not listed Tempe Arizona
Not listed Los Gatos California
Not listed Sacramento California
Not listed Tustin California
Not listed Westlake Village California
Not listed Colorado Springs Colorado
Not listed Wheat Ridge Colorado
Not listed Melbourne Florida
Not listed Pembroke Pines Florida
Not listed Augusta Georgia
Not listed South Bend Indiana
Not listed Auburn Maine
Not listed Marlborough Massachusetts
Not listed Chelsea Michigan
Not listed St Louis Missouri
Not listed Trenton New Jersey
Not listed Rochester New York
Not listed Burlington North Carolina
Not listed Wilmington North Carolina
Not listed Cleveland Ohio
Not listed Columbus Ohio
Not listed Oklahoma City Oklahoma
Not listed Carlisle Pennsylvania
Not listed Philadelphia Pennsylvania
Not listed Mt. Pleasant South Carolina
Not listed San Antonio Texas
Not listed Norfolk Virginia
Not listed Lakewood Washington
Not listed Renton Washington
Not listed Madison Wisconsin

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 12 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00696384, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 3, 2012 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00696384 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →